T-CELL
T-cell gamma/delta hepatosplenic lymphoma is a rare, well defined entity with typical immunophenotype, resistance to chemotherapy and short survival 1, 3, 4, 5 . It is derived from cytotoxic T-lymphocytes, which are preferentially located at the extranodal sites -red splenic pulp, skin, liver, intestine and bone marow. The neoplastic cells are CD 3+ and usually TCR (T-cell receptor) δ1+, TCR α/β negative, CD 56±, CD4 negative, CD8 negative and CD5 negative 6 . Most of the studied cases had nonactivated cytotoxic phenotype: T-cell intracellular antigen-1 (TIA-1) + and granzyme negative 1, 4 .
METHODS
A 48-year-old female was referred to our hospital with pancytopenia, splenomegaly (22 cm) and weight loss. There was no evidence of enlarged lymph nodes or hepatomegaly on the CT scan. We indicated splenectomy to reduce tumor mass and to eliminate hypersplenism. The patient was treated with 3 cycles of cytarabineplatinum containing regimen (EDHAP), 1 cycle of methotrexate-based regimen (IVAM) and 1 cycle of high-dose cytarabine (HAM) followed by high-dose chemotherapy (conditioning regimen BEAM 200) and autologous stem cell transplant.
RESULTS
The patient achieved complete remission (CR) in bone marrow in January 2004 after 2 cycles of chemotherapy (EDHAP). She remains in CR 21 months after diagnosis and 16 months after stem cell transplant. 
CONCLUSION
Current treatment modalities appear to be ineffective in most patients. Our case report suggests that aggressive first line treatment with platinum-cytarabine containing regimen followed by high-dose chemotherapy may lead to prolonged remission of gamma/delta hepatosplenic lymphoma 1, 2 . More studies are needed to determine the frequencies of immunophenotypes (activated versus nonactivated T-cells) and genetic changes, such as isochromosome arm 7q (ref. 1, 4 ). Gamma/delta T-cell lymphoma is probably not an homogenous entity. Precise identification of tumor cell origin is the first step to finding valuable prognostic factors.
